Reata slides on FDA concerns over rare disease drug

Reata Pharmaceuticals

08/08/2022 14:03

** Drug Developer Reata Pharmaceuticals Inc's  RETA.O 
shares slide 18.7% to $29 before the bell
    ** Says U.S. FDA still concerned about efficacy data for
co's experimental drug omaveloxolone for treatment of a rare
neurological disorder called Friedreich's ataxia  urn:newsml:reuters.com:*:nBwH0Hy8a
    ** FDA has a deadline of Nov. 30 to decide whether or not to
approve omaveloxolone
    ** Up to Friday's close, stock up ~35% YTD

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))